In 2007, the prevalence of high blood pressure (BP) was 36% in
Niger according to a recent survey by the World Health Organization (WHO).
Niger got involved in the May Measurement Month (MMM) campaign in 2017, 2018,
and 2019 to gain an understanding of the prevalence of selected cardiovascular
risk factors and high BP. The aim of this study was to screen for
cardiovascular risk factors with particular focus on high blood pressure (BP)
in Niger and thereby to raise awareness among the population of Niger about
raised BP and the associated risk to health. The city of Niamey served as our
study location during the month of May in 2017, 2018, and 2019. Volunteer
adults aged ≥18 years, who completed a pre-established questionnaire were
screened and had three sitting BP measurements taken. Hypertension was defined
as a systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg (based on the mean of the
second and third BP readings) or being on antihypertensive medication. In this
study, 2297 adults were screened, of which 42.9% were women and 57.1% were men.
Of the 2297 screened, 33.2% were found to be hypertensive of whom only 26
(3.4%) were recorded as being on treatment. Approximately 30% of those screened
were found to be obese or overweight. The MMM campaign in Niger highlights a
large number of people with hypertension can be screened opportunistically. In
the absence of systematic and population-based screening, the MMM campaign
should be continued annually in order to raise awareness of raised BP and its
complications among the population. High BP is a real public health danger, and
this study finds alarming figures that highlight the need for improved policies
for screening and management of hypertension. Raising awareness and improving
the detection of hypertension remain essential to reduce the burden of
cardiovascular disease.
Author
(s) Details
Ali I.
Touré
Lamorde National Teaching Hospital, Hospital Center University De
Niamey, Hospital Lamordé, G33J+GQ5, Niamey, Niger.
Dodo
Boubacar
Lamorde National Teaching Hospital, Hospital Center University De
Niamey, Hospital Lamordé, G33J+GQ5,
Niamey, Niger.
Dodo Boubacar
Lamorde National Teaching Hospital, Hospital Center University De Niamey,
Hospital Lamordé, G33J+GQ5, Niamey, Niger.
Kimba
Souley
Lamorde National Teaching Hospital, Hospital Center University De
Niamey, Hospital Lamordé, G33J+GQ5, Niamey, Niger.
Ali S.
Bonkano
Lamorde National Teaching Hospital, Hospital Center University De
Niamey, Hospital Lamordé, G33J+GQ5, Niamey, Niger.
Moustapha
Ousseini
Lamorde National Teaching Hospital, Hospital Center University De
Niamey, Hospital Lamordé, G33J+GQ5, Niamey, Niger.
Dari
Mossi
Lamorde National Teaching Hospital, Hospital Center University De
Niamey, Hospital Lamordé, G33J+GQ5,
Niamey, Niger.
Garba
I. Issoufou
Lamorde National Teaching Hospital, Hospital Center University De
Niamey, Hospital Lamordé, G33J+GQ5,
Niamey, Niger.
Moussa
Souna
Lamorde National Teaching Hospital, Hospital Center University De
Niamey, Hospital Lamordé, G33J+GQ5,
Niamey, Niger.
Ousseina
Bonkano
Lamorde National Teaching Hospital, Hospital Center University De
Niamey, Hospital Lamordé, G33J+GQ5,
Niamey, Niger.
Abdoul
Maji
Lamorde National Teaching Hospital, Hospital Center University De
Niamey, Hospital Lamordé,
G33J+GQ5, Niamey, Niger.
Halima Douma
Lamorde National Teaching Hospital, Hospital Center University De
Niamey, Hospital Lamordé, G33J+GQ5, Niamey, Niger.
Wei Wang
Imperial Clinical Trials Unit, Imperial College London, Stadium
House, 68 Wood Lane, London W12 7RH, UK.
Thomas
Beaney
Imperial Clinical Trials Unit, Imperial College London, Stadium
House, 68 Wood Lane, London W12 7RH, UK and Department of Primary Care and
Public Health, Imperial College London, St. Dunstan’s Road, London W6 8RP, UK.
Neil R. Poulter
Imperial Clinical Trials Unit, Imperial College London, Stadium
House, 68 Wood Lane, London W12 7RH, UK.
Please see the book here:- https://doi.org/10.9734/bpi/mmrnp/v7/2007
No comments:
Post a Comment